CTLA4 and triple-negative breast carcinoma: Using the 4T1 mouse model of triple negative breast cancer, where RT+CTLA-4 blockade elicits an anti-tumor T cell response that controls both the irradiated tumor and non-irradiated lung metastases and extends survival, we previously reported increased intratumoral CD8/CD4 ratio and CD8+ T cell clonality following RT+anti-CTLA-4 treatment [1].